Clinical and Vaccine Immunology

The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.  7. 2022

Nontypeable Haemophilus influenzae Redox Recycling of Protein Thiols Promotes Resistance to Oxidative Killing and Bacterial Survival in Biofilms in a Smoke-Related Infection Model.  7. 2022

Antibodies to variable domain 4 linear epitopes of the chlamydia trachomatis major outer membrane protein are not associated with chlamydia resolution or reinfection in women.  5. 2020

Erratum: "A Common Food Glycan, Pectin, Shares an Antigen with Streptococcus pneumoniae Capsule" [mSphere, 5, 2, (2020), (e00074-20)] DOI: 10.1128/mSphere.00074-20.  5. 2020

A Common Food Glycan, Pectin, Shares an Antigen with Streptococcus pneumoniae Capsule.  5. 2020

Genotypic and phenotypic diversity of herpes simplex virus 2 within the infected neonatal population.  4. 2019

Quantitative proteomics uncovers the interaction between a virulence factor and mutanobactin synthetases in Streptococcus mutans.  4. 2019

Rapid bladder interleukin-10 synthesis in response to uropathogenic Escherichia coli is part of a defense strategy triggered by the major bacterial flagellar filament fliC and contingent on TLR5.  4. 2019

The modified surface killing assay distinguishes between protective and nonprotective antibodies to PspA.  4. 2019

Staphylococcus aureus biofilm growth on cystic fibrosis airway epithelial cells is enhanced during respiratory syncytial virus coinfection.  3. 2018

Development, interlaboratory evaluations, and application of a simple, high-throughput Shigella serum bactericidal assay.  3. 2018

The pneumococcal serotype 15C capsule is partially O-acetylated and allows for limited evasion of 23-valent pneumococcal polysaccharide vaccine-elicited anti-serotype 15B antibodies.  24. 2017

A three-dimensional cell culture system to model RNA virus infections at the bloodbrain barrier.  2. 2017

Plasmablast response to primary rhesus cytomegalovirus (CMV) infection in a monkey model of congenital CMV transmission.  24. 2017

The predominant CD4⁺ Th1 cytokine elicited to chlamydia trachomatis infection in women is tumor necrosis factor alpha and not interferon gamma.  24. 2017

Assignment of opsonic values to pneumococcal reference serum 007sp for use in opsonophagocytic assays for 13 serotypes.  24. 2017

Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens.  2. 2017

The case for adopting the "species complex" nomenclature for the etiologic agents of cryptococcosis.  2. 2017

The live attenuated cholera vaccine CVD 103-HgR primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild-type vibrio cholerae.  24. 2017

Monoclonal antibodies to Shigella lipopolysaccharide are useful for vaccine production.  23:681-688. 2016

Simultaneous antibiofilm and antiviral activities of an engineered antimicrobial peptide during virus-bacterium coinfection.  1. 2016

Pf filamentous phage requires UvrD for replication in Pseudomonas aeruginosa.  1. 2016

Resolution of Chlamydia trachomatis infection is associated with a distinct T cell response profile.  22:1206-1218. 2015

Multivalent pneumococcal protein vaccines comprising pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protection.  22:1079-1089. 2015

International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE.  22:957-964. 2015

Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units.  22:313-318. 2015

Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins..  22:213-220. 2015

Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.  22:129-135. 2015

Phase i/ii randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-Uninfected adult participants.  21:1589-1599. 2014

Commercially available complement component-depleted sera are unexpectedly codepleted of ficolin-2.  21:1323-1329. 2014

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.  21:212-226. 2014

Blood collection tubes influence serum ficolin-1 and ficolin-2 levels.  21:51-55. 2014

IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States.  21:1054-1060. 2014

Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.  21:940-948. 2014

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli (Clinical and Vaccine Immunology (2013) 20, 11, (1764-1770)).  21:602. 2014

Invasive and Noninvasive Streptococcus pneumoniae Capsule and Surface Protein Diversity following the Use of a Conjugate Vaccine.  20:1711-1718. 2013

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.  20:1764-1770. 2013

Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.  20:1549-1558. 2013

Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.  20:540-550. 2013

The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci In Vitro.  19:1574-1582. 2012

Device for carrying blood samples at 37°C for cryoglobulin test.  19:1555-1556. 2012

Impaired function of antibodies to pneumococcal surface protein A but Not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus.  19:1360-1369. 2012

Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20.  19:835-841. 2012

PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.  19:891-896. 2012

Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N.  19:909-913. 2012

Development of an automated and multiplexed serotyping assay for Streptococcus pneumoniae.  18:1900-1907. 2011

Establishment of a new human pneumococcal standard reference serum, 007sp.  18:1728-1736. 2011

Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.  18:135-142. 2011

PsrP, a protective pneumococcal antigen, is highly prevalent in children with pneumonia and is strongly associated with clonal type.  17:1672-1678. 2010

Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS clinical trials group trial A5181.  17:1452-1459. 2010

Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids.  17:393-401. 2010

Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.  17:80-86. 2010

Lipoprotein lipase and hydrofluoric acid deactivate both bacterial lipoproteins and lipoteichoic acids, but platelet-activating factor-acetylhydrolase degrades only lipoteichoic acids.  16:1187-1195. 2009

Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.  16:376-381. 2009

Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses.  16:288-290. 2009

Abnormal micronuclear telomeres lead to an unusual cell cycle checkpoint and defects in Tetrahymena oral morphogenesis..  7:1712-1723. 2008

Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.  15:1529-1535. 2008

Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in Finland who had acute otitis media or were nasopharyngeal carriers.  15:1555-1563. 2008

Seroincidence of recent human immunodeficiency virus type 1 infections in China.  14:1384-1386. 2007

Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.  14:926-928. 2007

Evaluation of the LIAISON chemiluminescence immunoassay for diagnosis of syphilis.  14:710-713. 2007

Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.  13:1177-1179. 2006

Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.  13:1004-1009. 2006

Eukaryotic release factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in Saccharomyces cerevisiae.  5:1378-1387. 2006

In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei.  5:1276-1286. 2006

Platelet-activating factor-acetylhydrolase can monodeacylate and inactivate lipoteichoic acid.  13:452-458. 2006

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.  13:165-169. 2006

Serum resistance-associated protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma brucei.  5:132-139. 2006

Phenotypic switching in Candida glabrata accompanied by changes in expression of genes with deduced functions in copper detoxification and stress..  4:1434-1445. 2005

Unique aspects of gene expression during Candida albicans mating and possible G(1) dependency..  4:1175-1190. 2005

Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.  12:19-27. 2005

Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS.  11:792-794. 2004

Multilaboratory Evaluation of a Viability Assay for Measurement of Opsonophagocytic Antibodies Specific to the Capsular Polysaccharides of Streptococcus pneumoniae.  10:1019-1024. 2003

Alpha-pheromone-induced "shmooing" and gene regulation require white-opaque switching during Candida albicans mating..  2:847-855. 2003

Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.  10:616-621. 2003

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.  10:514-519. 2003

A Saccharomyces cerevisiae mutant unable to convert glucose to glucose-6-phosphate accumulates excessive glucose in the endoplasmic reticulum due to core oligosaccharide trimming.  2:534-541. 2003

Relationship between switching and mating in Candida albicans..  2:390-397. 2003

TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative youths.  10:399-404. 2003

Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles.  10:323-328. 2003

Cell biology of mating in Candida albicans..  2:49-61. 2003

Peripheral blood lymphocyte subsets in adolescents: A longitudinal analysis from the REACH project.  9:959-965. 2002

Roles of TUP1 in switching, phase maintenance, and phase-specific gene expression in Candida albicans..  1:353-365. 2002

Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera.  8:528-533. 2001

Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.  8:245-250. 2001

Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus.  8:273-278. 2001

A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multiple pneumococcal serotypes (multibead assay).  7:486-489. 2000

Towards a synthetic pneumococcal vaccine: Synthetic oligosaccharides as tools for improving the specificity of enzyme-linked immunosorbent assays [1] (multiple letters).  7:325. 2000

Pneumococcal capsular polysaccharide preparations may contain non-C- polysaccharide contaminants that are immunogenic.  6:519-524. 1999

Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.  6:921-923. 1999

Measurement of induced cytokines in AIDS clinical trials using whole blood: A preliminary report.  5:556-560. 1998

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines.  3:378-386. 1996

Humoral antibody to Mobiluncus curtisii, a potential serological marker for bacterial vaginosis.  3:567-569. 1996